<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-149162</identifier>
<setSpec>0004-0614</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">No disponible</dc:title>
<dc:description xml:lang="en">Objetive: To know the dermatologic side effects of intravesical treatment with Mitomycin C in non muscle invasive bladder cancer. Methods: We describe two cases of palm and plantar dermatitis after such treatment. Results: We describe two types of dermatitis pathogenesis during treatment with intravesical Mitomycin C: contact dermatitis and delayed hypersensitivity dermatitis. Conclusions: Contact dermatitis of non-allergic origin is a common side effect described in many instances in the literature, on the other hand exists dermatitis secondary to delayed hypersensitivity type IV much less common, requiring treatment with corticosteroids (AU)</dc:description>
<dc:creator>Castillo Pacheco, Carlos</dc:creator>
<dc:creator>González Satue, Carlos</dc:creator>
<dc:creator>Martínez Rodríguez, Roberto</dc:creator>
<dc:creator>Colomer Gallardo, Anna</dc:creator>
<dc:creator>Ibarz Servio, Luis</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Conocer los efectos secundarios dermatológicos del tratamiento con Mitomicina C endovesical en el cáncer de vejiga no músculo invasivo. Métodos: Se describen dos casos de dermatitis palmo plantar durante dicho tratamiento. Resultado: Se describen dos tipos de etiopatogenia en dermatitis durante el tratamiento con Mitomicina C endovesical, dermatitis por contacto y dermatitis por hipersensibilidad retardada. Conclusiones: La dermatitis por contacto de etiología no alérgica es un efecto secundario frecuente, se han descrito muchos casos en la literatura, por otro lado existe la dermatitis por mecanismo de hipersensibilidad retardada tipo IV es mucho menos frecuente y requiere tratamiento con corticoesteroides (AU)</dc:description>
<dc:source>Arch Esp Urol;69(2): 89-91, mar. 2016. ilus</dc:source>
<dc:identifier>ibc-149162</dc:identifier>
<dc:title xml:lang="es">Efectos secundarios de la administración de Mitomicina C intravesical: dermatitis por hipersensibilidad retardada</dc:title>
<dc:subject>^d3576^s22045</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d3576^s22074</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7146^s22016</dc:subject>
<dc:subject>^d3892^s22016</dc:subject>
<dc:subject>^d7146^s22036</dc:subject>
<dc:subject>^d29961^s22020</dc:subject>
<dc:subject>^d7146^s22012</dc:subject>
<dc:subject>^d3576^s22039</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d3892^s22012</dc:subject>
<dc:subject>^d4977^s22036</dc:subject>
<dc:subject>^d4977^s22057</dc:subject>
<dc:subject>^d4977^s22012</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d19057</dc:subject>
<dc:type>article</dc:type>
<dc:date>201603</dc:date>
</metadata>
</record>
</ibecs-document>
